Nasal Delivery of Spray Dried Biologics
The nasal route offers a number of benefits over some of the traditional routes of administration for biologics.
Upperton Pharma Services offers services for the development and manufacturing of pharmaceutical dosage forms.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Upperton Pharma Solutions is a UK-based contract development and manufacturing organisation (CDMO) that specialises in oral, nasal and pulmonary dosage forms. We offer a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical and commercial manufacture.
With more than 25 years of industry experience, Upperton excels in rapid product introductions, achieving the transition in as little as 4-6 weeks. Our project delivery is unparalleled and designed specifically to align with the values and innovation of small to mid-sized pharma companies. With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise that covers all layers of our operations.
Our science-led approach drives two-way open dialogue and transparency. We have proven expertise in the development, scale-up, manufacturing and testing of oral, pulmonary and nasal drug products. For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.
Upperton’s science-led approach is supported by expertise at every stage of the development process. We offer services for formulation development, Phase I-III clinical supply, process scale-up and optimisation, registration activities, and analytical development and validation.
Our leadership team brings a wealth of experience in guiding products from initial development through to commercial production. The team’s commitment to quality and innovation has been recognised through numerous awards, such as the King’s Award for Enterprise 2023 and Pharma Industry Awards UK.
Upperton’s mission is to develop and manufacture high-quality drug products while fostering strong client relationships. We offer a variety of services, including formulation development, clinical supply from Phase I to Phase III, process scale-up, registration activities, and analytical development and validation.
Upperton operates a state-of-the-art 50,000ft² development and manufacturing facility, Trent Gateway, in Nottingham, UK. Trent Gateway features ten individual good manufacturing practice (GMP) manufacturing suites, quality control laboratories, and dedicated spaces for analytical and formulation development. These facilities are equipped to process a variety of non-sterile dosage forms, including solids, liquids, semi-solids, and both nasal and inhaled products.
The Trent Gateway site supports a range of project requirements, from early formulation development to clinical trial supply and niche-scale commercial manufacturing. The research and development area spans 10,000ft², featuring laboratories for dosage form development, pilot plants for potent processing, and a dedicated analytical team.
The facility’s GMP manufacturing suites are designed to support oral, pulmonary, and nasal dosage forms, with capabilities for sterile processing and high-potency containment. Quality control is maintained through 8,000ft² of analytical laboratories, which are equipped with advanced technology for ensuring product quality.
Upperton offers expertise in developing a range of small-molecule and biologic dosage forms, providing support from early feasibility studies through to clinical manufacture. We specialise in the development of both simple and complex oral dosage forms, including powders, capsules, and tablets. We can also produce IR, MR, SR and Minitabs tablets, as well as API, powder blend and lipid capsules.
Our UpperNose™ approach streamlines and accelerates the process of developing nasal dosage forms, making it more accessible to small and mid-sized innovators. UpperNose™ supports both liquid and dry powder formulations.
Upperton specialises in the development of pulmonary drug products through expertise in formulation development, particle engineering and device selection. We offer both dry powder and liquid formulation options, addressing factors such as solubility, stability, and target dose delivery.
Upperton caters to an array of drug development needs, from preclinical stages through to late-phase development and commercial manufacturing. Our services are tailored to meet the unique challenges of each project and include feasibility studies to optimise spray-drying parameters, formulation development to ensure efficient API delivery, stability studies to verify storage conditions, and scale-up studies to prepare for GMP manufacturing.
Upperton’s analytical capabilities play a vital role in ensuring that products transition smoothly from development to clinical trials. Benefit from a science-led and structured approach that supports a seamless progression through the development pathway.
Upperton tailors projects to fit specific client timelines and requirements, prioritising effective communication and collaboration in project delivery. Each project is assigned a project manager who coordinates all activities and ensures that transparency is maintained through regular updates.
Project teams at Upperton are composed of experts from various disciplines, including development, GMP, analytical, quality analysis, and technical transfer. The inclusion of an Executive Leadership Team member in every project ensures that decisions are made under expert guidance.
The nasal route offers a number of benefits over some of the traditional routes of administration for biologics.
As a leading contract development and manufacturing organisation, Upperton's defining traits lie in our adaptability and nimbleness, enabling rapid product introduction within 4-6 weeks.
Through our science-led approach and extensive experience in product development, Upperton can support you with aseptic and terminally sterilised small volume liquids, as well as lyophilised and spray dried powders for parenteral, ocular and pulmonary delivery.
Spray drying is the term used to succinctly describe a robust and scalable drying process in which liquids are first sprayed (atomised) to create droplets that are captured in a heated air or gas stream.
Currently, most brain/CNS therapies are administered orally and enter the brain via the systemic circulation However, in recent years, there have been a growing number of drug products approved that look to target the brain following intranasal delivery.
Completing a Phase I clinical study is a major milestone for your development programme and there are multiple considerations for the team depending on the drug product used in the study and the clinical outcome.
Interest in developing nasal dosage forms has increased significantly in the last two years, driven by a number of recent successful FDA approvals such as BAQSIMI® (dry-powder glucagon) NEFFY® (liquid epinephrine spray) and NARCAN® (liquid naloxone spray).
Traditionally, spray drying has been utilised as a useful technology for enhancing the delivery of small molecules via the oral route, in either tablet or capsule dosage forms. However, in more recent times, spray drying has emerged as the method of choice for creating dry powders for delivery in an increasing range of products incorporating oral, pulmonary, nasal, and injectable dosage forms.
Biopharma companies are under continued pressure to respond to the global increase in acute respiratory conditions, with the global market for inhalation drug delivery devices expected to reach $20.7bn by 2031, growing at a compound annual growth rate (CAGR) of 4.4%
The administration of drugs into the lung is a well-established delivery route for the treatment of a wide range of pulmonary ailments.
Upperton, a leading contract development and manufacturing organisation (CDMO) based in Nottingham, UK, has enhanced its high-precision filling capability with the installation and commissioning of the Fill2Weight gravimetric powder filling machine from 3P innovation.
Industry observers regard Upperton’s win this year as an important milestone.
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford.
Upperton Pharma Solutions is delighted to announce its recognition as the winner of the Business Expansion award in the Integrated Manufacturing category at the 2025 Pharmaceutical Technology Excellence Awards.
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with the appointment of Michael Mellor-Clark as Chief Commercial Officer (CCO).
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO Leadership Awards.
Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions has completed the build of its new sterile manufacturing facility in Nottingham, UK.
Meet Upperton Pharma at BIO Europe, Stockholm, 4-6 November 2024.
Upperton Pharma Solutions has been awarded Pharma Project of the Year – Large – at the Pharma Industry Awards UK 2024, held at the International Convention Centre (ICC) in Birmingham on Wednesday 18 September. The prestigious event celebrated excellence across the pharmaceutical and biotech sectors, recognising achievements in various categories.
Upperton Pharma Solutions, a contract development and manufacturing organisation (CDMO), is pleased to announce the successful completion of a Medicines and Healthcare products Regulatory Agency (MHRA) inspection at its newly commissioned 50,000ft² development and good manufacturing practice (GMP) manufacturing facility in Nottingham, UK.
Meet the Upperton team at CPHI Milan, on Stand 5D138 and connect with our experts to discover more about how we can bring success to your drug development journey.
Upperton offers formulation development services to accelerate First in Human studies and advance projects toward clinical trials. Supporting projects from proof of concept and feasibility through to scale-up and clinical manufacture, Upperton specialises in a range of oral, nasal, and pulmonary dosage forms.
Upperton offers analytical services designed to support the development, monitoring, and quality control testing of pharmaceutical products. Our analytical team focus on understanding the physico-chemical properties of active pharmaceutical ingredients (APIs), as well as identifying potential stability challenges and excipient incompatibilities that may arise during product development.
Upperton provide clinical supply for Phase I, Phase II and Phase III, specialising in oral, nasal and pulmonary dosage forms.
Upperton provides a flexible and dynamic approach to GMP manufacturing. From first-in-human (FIH) through to Phase III clinical supplies manufacturing at our MHRA and Home Office-approved (I-IV) GMP facility, Trent Gateway.
Upperton's team of experts can support you in all aspects of scale-up and technology transfer through our state-of-the-art development and manufacturing facility. With knowledge across all layers of our business, we ensure a seamless transfer and reduced risk of advancing into later stages.
Through a science-led approach and extensive experience in product development, Upperton's team can support you with aseptic and terminally sterilised small volume liquids, as well as lyophilised and spray dried powders for parenteral, ocular and pulmonary delivery.
Oral administration remains the most widely used route for the successful delivery of active pharmaceuticals to patients. Upperton is your trusted partner for oral solid-dose (OSD) products.
Upperton has developed UpperNose™, a nasal product development approach designed to streamline the development process for nasal dosage forms. UpperNose™ aims to facilitate the development of molecules, ensuring a smooth transition from early-stage development to clinical trials.
This video gives an overview of Upperton Pharma Solutions' GMP manufacturing capabilities.
This video offers a summary of Upperton Pharma Solutions' product and service offerings.
Webinar exploring Upperton's process of developing the UpperNose and other nasal dosage forms.
This video goes through the sections of Upperton Pharma Solutions' R&D lab and the functions they fulfil.